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A randomized, double-blind, phase 2b
proof-of-concept clinical trial in early
Alzheimer’s disease with lecanemab, an
anti-Aβ protofibril antibody
Chad J. Swanson1, Yong Zhang1, Shobha Dhadda1, Jinping Wang1, June Kaplow1, Robert Y. K. Lai2, Lars Lannfelt3,4,
Heather Bradley1, Martin Rabe1, Akihiko Koyama1, Larisa Reyderman1, Donald A. Berry5, Scott Berry5,
Robert Gordon2, Lynn D. Kramer1 and Jeffrey L. Cummings6*

Abstract
Background: Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated
amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized
double-blind clinical trial, utilized a Bayesian design with response-adaptive randomization to assess 3 doses across
2 regimens of lecanemab versus placebo in early Alzheimer’s disease, mild cognitive impairment due to Alzheimer’s
disease (AD) and mild AD dementia.
Methods: BAN2401-G000-201 aimed to establish the effective dose 90% (ED90), defined as the simplest dose that
achieves ≥90% of the maximum treatment effect. The primary endpoint was Bayesian analysis of 12-month clinical
change on the Alzheimer’s Disease Composite Score (ADCOMS) for the ED90 dose, which required an 80%
probability of ≥25% clinical reduction in decline versus placebo. Key secondary endpoints included 18-month
Bayesian and frequentist analyses of brain amyloid reduction using positron emission tomography; clinical decline
on ADCOMS, Clinical Dementia Rating-Sum-of-Boxes (CDR-SB), and Alzheimer’s Disease Assessment Scale-Cognitive
Subscale (ADAS-Cog14); changes in CSF core biomarkers; and total hippocampal volume (HV) using volumetric
magnetic resonance imaging.
Results: A total of 854 randomized subjects were treated (lecanemab, 609; placebo, 245). At 12 months, the 10-mg/
kg biweekly ED90 dose showed a 64% probability to be better than placebo by 25% on ADCOMS, which missed
the 80% threshold for the primary outcome. At 18 months, 10-mg/kg biweekly lecanemab reduced brain amyloid
(−0.306 SUVr units) while showing a drug-placebo difference in favor of active treatment by 27% and 30% on
ADCOMS, 56% and 47% on ADAS-Cog14, and 33% and 26% on CDR-SB versus placebo according to Bayesian and
frequentist analyses, respectively. CSF biomarkers were supportive of a treatment effect. Lecanemab was welltolerated with 9.9% incidence of amyloid-related imaging abnormalities-edema/effusion at 10 mg/kg biweekly.
(Continued on next page)
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Conclusions: BAN2401-G000-201 did not meet the 12-month primary endpoint. However, prespecified 18-month
Bayesian and frequentist analyses demonstrated reduction in brain amyloid accompanied by a consistent reduction
of clinical decline across several clinical and biomarker endpoints. A phase 3 study (Clarity AD) in early Alzheimer’s
disease is underway.
Trial registration: Clinical Trials.gov NCT01767311.
Keywords: Alzheimer’s disease, Amyloid, Lecanemab, BAN2401, Clinical trial, Biomarker, ADCOMS, Amyloid PET,
Neurofilament light, Neurogranin, p-tau

Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that slowly impairs cognition and function [1–
3]. AD occurs on a continuum, progressing from asymptomatic preclinical AD, to mild cognitive impairment due
to AD, and to mild, moderate, and severe AD dementia.
Amyloid β protein (Aβ) exists in various conformational
states, including soluble monomers, soluble aggregates of
increasing size (e.g., oligomers, protofibrils), and insoluble
fibrils and plaque [4–6]. Soluble Aβ aggregates have been
shown to be more toxic than monomers or insoluble fibrils [4, 6–10], and we hypothesized that reducing these
soluble Aβ aggregates could represent an effective treatment approach in early stages of AD [4, 11, 12].
Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that binds to soluble Aβ aggregates (oligomers and protofibrils) with high selectivity over
monomer (> 1000-fold) and insoluble fibrils (approximately 10–15 fold) [13–16]. Reduction of Aβ protofibrils
and Aβ plaque, as well as prevention of Aβ deposition
before plaques develop, has been demonstrated using
the murine version of lecanemab in animal models [12–
14, 17, 18]. The antibody was well tolerated in a phase 1
study, with dose proportional exposure [19]. On the
basis of these findings, a phase 2b proof-of-concept,
dose-ranging efficacy study using a novel Bayesian adaptive design was initiated to assess the effects of lecanemab in subjects with mild cognitive impairment due to
AD and mild AD dementia, collectively termed early
Alzheimer’s disease.
BAN2401-G000-201 (Study 201) employed a Bayesian
adaptive design with response adaptive randomization,
involving frequent blinded interim analyses intended to
assess for early success or futility, and designed to update subsequent subject allocation probabilities based on
the predicted 12-month outcome modeled on all available clinical data on the Alzheimer’s Disease Composite
Score (ADCOMS). In this design, a computer algorithm
assessed accumulating ADCOMS data to allocate more
subjects to a dose or doses that were most likely to be
the ED90 target dose (defined as the simplest treatment
group that achieves at least 90% of the modeled maximum treatment effect), while putting fewer subjects on

less effective doses (NOTE: once subjects were randomized to a dose, they stayed on that dose for the duration
of the study). Each interim analysis and the resulting update to subject allocation was implemented seamlessly
while remaining completely blinded to subjects, sites,
and the Sponsor. The choice of design was deemed a
suitable approach to efficiently balance the desired potential for rapid decision-making and the need to establish clinical proof-of-concept [20]. The use of Bayesian
methodology with a 12-month primary endpoint in this
18-month study was intended to afford the opportunity
to move as early as possible into phase 3 if an early
rigorous success criterion was met at any interim analysis, or to simply proceed per protocol to full
randomization and study completion at 18 months if this
condition was not met. Understanding the importance
of 18-month data in the context of AD clinical trials
assessing slowing of disease progression, all randomized
subjects were to complete the full 18 months of treatment. The study was prospectively designed to analyze
the 18-month results with Bayesian and frequentist (conventional) statistics regardless of whether the primary
endpoint was met at 12 months.

Methods
Design

A full, detailed manuscript on the lecanemab Study 201
design has been previously published [20] and additional
details can be found in the study protocol (supplementary appendix A). Study 201 (NCT01767311) was an 18month, multicenter, double-blind, placebo-controlled
Bayesian design clinical trial employing response adaptive randomization across placebo and five lecanemab
arms (2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly, 10 mg/kg biweekly) to assess
safety and efficacy in subjects with early Alzheimer’s disease (Fig. 1). To maintain the blind, all subjects received
biweekly infusions of either placebo or lecanemab.
Following a fixed randomization period for the first
196 subjects (N = 56 on placebo; N = 28 in each lecanemab arm), response-adaptive randomization was implemented where dose allocation probabilities were updated
at each blinded interim analysis, conducted every 50
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Fig. 1 Lecanemab Study 201 study design. Study 201 (NCT01767311) was an 18-month, multicenter, double-blind, placebo-controlled Bayesian
design clinical trial employing response adaptive randomization across placebo and five lecanemab arms (2.5 mg/kg biweekly, 5 mg/kg monthly,
5 mg/kg biweekly, 10 mg/kg monthly, 10 mg/kg biweekly) to assess safety and efficacy in subjects with early Alzheimer's disease. At the first three
interim analyses, if there is a .5% posterior probability that the most likely ED90 is superior to placebo by the (clinically significant difference; 25%),
the trial will stop early for futility. Beginning at the 350-subject IA, and continuing to completion of the trial, the futility criterion is increased to
7.5%. Interim monitoring for early success occurs at each IA beginning when 350 subjects have been enrolled. At this point, if enrollment were to
stop for early success, enough subjects would be available to complete the trial so that the full dose response could be modeled. If there is a
.95% posterior probability that the most likely ED90 is better than placebo by the CSD, then early success is declared. Enrollment is stopped, but
all randomized subjects continue for the full 18-month duration of the study. If the trial is not stopped early for futility or success, then trial
success is evaluated at the completion of the trial when both accrual and follow-up for the primary endpoint are complete. At that time, if there
is a .80% probability that the most likely ED90 is better than placebo by the CSD, the trial will be considered a success. R, randomization

randomized subjects until the approximate target of 800
subjects were randomized (196, 250, 300, 350, …, 800),
with the remaining 56 randomized subjects allocated according to the probabilities determined at the 800 subject interim analysis. The Bayesian design aimed to
identify the effective dose 90% (ED90), defined as the
simplest dose that achieves ≥90% of the maximum treatment effect, and to allocate more subjects to the most
likely ED90 dose(s) at each interim analysis [19]. “Simplest” means the earliest in the order of convenience (5
mg/kg monthly, 10 mg/kg monthly, 2.5 mg/kg biweekly,
5 mg/kg biweekly, 10 mg/kg biweekly). Monitoring for
futility was initiated at the first interim analysis (IA) and
was based on the dose identified as the most likely
ED90. The trial would have stopped early for futility at
any of the first three IAs if there was a <5% posterior
probability that the most likely ED90 is superior to placebo by the clinically significant difference (25%). From
the 350-subject IA until the completion of the trial, the
futility criterion was increased to 7.5%. Interim

monitoring for early success occurred at each IA beginning when 350 subjects had been enrolled, where a .95%
posterior probability that the most likely ED90 is better
than placebo by the CSD was required. The trial was designed to continue to full completion if neither futility
nor early success was achieved according to criteria. At
full study completion, the study was considered a success if an 80% probability that the most likely ED90 was
better than placebo by the CSD was achieved. In this
phase 2 trial, success is defined as a drug effect that exceeds the placebo rate by ≥25%, rather than only being
superior to placebo. We chose this criterion to ensure
that any early signal of success would likely indicate a
robust treatment effect [20]. Upon full randomization,
three additional interim analyses were implemented at
3-month intervals from the time of the last subject randomized to assess for early success or futility prior to
the final 12-month Bayesian analysis. Subjects remained
on the assigned dose/regimen throughout the trial. The
adaptive randomization probability for placebo mirrors
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the probability for the most likely ED90 dose. Details on
adaptive randomization probabilities are found in the
Simulation Plan provided in the supplemental appendix
B. The Bayesian computer algorithm was finalized prior
to study start (i.e., not modified during the course of the
study). ADCOMS, a score generated from 12 items collected with 3 well-established clinical scales [21], was
employed as a sensitive measure of clinical decline in
early Alzheimer’s disease intended to aid in driving
response-adaptive subject allocation. The trial was approved by the institutional review board or independent
ethics committee at each center and all subjects provided informed consent.
There was a notable protocol amendment during
the course of the study related to a safety observation
for apolipoprotein E4 (ApoE4) gene carriers receiving
the highest dose of lecanemab. Emerging data from
the study just prior to the 350 subject interim analysis indicated that ApoE4 positive homozygous individuals on the highest dose of lecanemab (10 mg/kg
biweekly) had the highest risk of developing symptomatic amyloid-related imaging abnormalities-edema/
effusion (ARIA-E). Following comprehensive data review, one regulatory authority requested that ApoE4
carriers (homozygous and heterozygous; approximately
70% of the overall subject population) no longer be
administered the 10 mg/kg biweekly dose of lecanemab going forward, and this approach was adopted
for all subsequent randomizations. At the same time,
a request was made to discontinue from study drug
administration, without exception, all ApoE4 carriers
(homozygous and heterozygous) who were randomized to the 10 mg/kg biweekly dose and were on
study for less than 6 months. Additional details are
available in Supplementary Appendix C.
Subjects

Participants comprised 2 subgroups: mild cognitive
impairment due to AD or mild AD dementia. All
subjects were confirmed amyloid positive via amyloid
positron emission tomography (PET) or cerebrospinal
fluid (CSF) Aβ1–42 for eligibility. Key inclusion criteria
included objective impairment in episodic memory
(on Wechsler Memory Scale-IV Logical Memory II
[WMS-IV LMII]), Mini Mental State Examination
(MMSE) score equal to or greater than 22 at screening and baseline (amended to MMSE 22–28 in EU,
except Italy), and naïve to or on stable dose (12
weeks) of approved AD medications.
Endpoints and assessments

The primary endpoint was change from baseline at 12
months on ADCOMS [20]. Key secondary endpoints
were change from baseline at 18 months in brain

Page 4 of 14

amyloid by PET Standard Uptake Value ratio (SUVr) in
an optional sub-study of consenting participants,
ADCOMS, Clinical Dementia Rating-Sum-of-Boxes
(CDR-SB), Alzheimer Disease Assessment ScaleCognitive Subscale (ADAS-Cog14), CSF biomarkers (optional sub-study), and total hippocampal volume using
volumetric magnetic resonance imaging (vMRI). An
evaluation of the efficacy of lecanemab compared to placebo at 18 months for ADCOMS, CDR-SB, and ADASCog14 within the mild cognitive impairment due to AD
(MCI) and mild AD dementia clinical subgroups was
also a key secondary endpoint. Subjects were monitored
for adverse events at all visits. All subjects with ARIA-E
as assessed by MRI were discontinued immediately per
protocol, regardless of radiologic severity or symptomatic status. ADCOMS, ADAS-Cog14, CDR-SB, and
MMSE were collected every 3 months during the study.
CSF samples were collected in consenting participants at
baseline, 12, and 18 months, with biomarkers (Aβ1–42,
phosphorylated tau [p-tau], total tau [t-tau] as well as
exploratory biomarkers, including neurogranin, and neurofilament light chain [NfL]) measured by ELISA and
SIMOA. Additional details can be found in the study
protocol (supplementary appendix A).
Statistical analyses

Bayesian dose-response data for the primary endpoint
were modeled with a 2-dimensional (dose-by-frequency)
first-order normal dynamic linear model, where Normal
and Inverse-Gamma priors were used. The primary endpoint was met if the Bayesian analysis, when all subjects
completed 12 months of treatment, met the threshold of
an 80% probability that the ED90 dose achieved at least
25% less clinical decline compared to placebo on
ADCOMS. This proof-of-concept study was powered for
decline on active treatment being at least 25% less than
decline on placebo, which was defined as the clinically
significant difference (CSD) for this study. The 12month primary analysis was intended to allow for the
opportunity to accelerate decision making for phase 3. A
sample size of approximately 800 subjects was deemed
sufficient to meet the 80% probability threshold for the
primary endpoint according to treatment-response assumptions [19].
Bayesian and conventional (frequentist) statistical analyses were prospectively defined prior to study start for
key secondary endpoints (change from baseline for the
treatment groups compared to placebo at 18 months for
PET SUVr, ADCOMS, ADAS-Cog14, CDR-SB, vMRI,
and CSF biomarkers). Bayesian analyses did not require
adjustment for multiplicity by nature of the Bayesian approach. Conventional analyses were performed using a
mixed effects model with repeated measures (MMRM)
comparing placebo to active arms. All listed p-values for
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key secondary endpoints using conventional statistics
are nominal, and no correction was applied for multiplicity. In addition to analyses for individual dose arms, a
prospectively defined analysis of key secondary endpoints was performed on subjects from the combined
two 10 mg/kg dose regimens, in an attempt to balance
the number of ApoE4-positive subjects lost in the 10
mg/kg biweekly dose group brought about by the Regulatory Authority-imposed amendment to the design. The
MMRM analysis used treatment group, visit, clinical
subgroup (MCI due to AD, Mild AD dementia), the
presence or absence of ongoing AD treatment at baseline, ApoE4 status, world region, and treatment groupby-visit interaction as factors, and baseline value as covariate. Safety assessments were summarized by treatment group using descriptive statistics. There was no
sample size analysis for the CSF substudy and results for
biomarker analyses are presented descriptively. Subjects
from the 10 mg/kg biweekly and monthly doses were
pooled in the CSF substudy biomarker analyses to increase the sample size.
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Role of the funding source

This trial was funded by Eisai Inc. Authors from Eisai
Inc. had input into the study design; in the collection,
analysis, and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication. The corresponding author had full access to all
the data in the study and had final responsibility for the
decision to submit for publication.

Results
A total of 856 subjects were randomized and 854 were
treated (lecanemab, 609; placebo, 245) between December 2012 and November 2017 at 117 sites across North
America (the USA and Canada), Europe (France,
Germany, Italy, Netherlands, Spain, Sweden, and the
UK), and the Asia-Pacific region (Japan and South
Korea).
Allocation of subjects to doses via the adaptive
randomization design are shown in Fig. 2. The adaptive
randomization algorithm identified both 10 mg/kg biweekly and 10 mg/kg monthly early in the study as

Fig. 2 Randomization allocations by treatment group per protocol-defined interim analyses. The response adaptive randomization correctly
allocated subjects into the dose groups likely to be ED90 doses (10 mg/kg monthly and biweekly) as early as the first interim analysis at 197
subjects, with both emerging by the 300th subject randomized, and these doses remained the most likely doses to demonstrate efficacy
throughout the remainder of the study. However, before the interim analysis of 350 subjects, Health Authorities restricted randomization around
ApoE4 carrier status, whereby ApoE4 carriers (hetero- or homozygous) were not to be randomized to the 10 mg/kg biweekly dose going forward.
As a consequence, the response adaptive randomization algorithm was revised. After each subsequent interim analysis (starting with 350 subjects
randomized), the randomization probability vector was split between ApoE4 carrier and non-carrier strata to ensure no ApoE4 carriers were
enrolled on the 10 mg/kg biweekly dose (more details in Appendix C). At the same time, the revised response adaptive randomization preserved
the overall randomization probabilities
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potential ED90 doses, and they received the greatest allocation of subjects accordingly. The number of subjects
randomized per dose were placebo = 247; 2.5 mg/kg biweekly = 52; 5 mg/kg monthly = 51; 5 mg/kg biweekly =
92; 10 mg/kg monthly = 253; 10 mg/kg biweekly = 161
(Fig. 2). Although the lecanemab 10 mg/kg biweekly dose
was identified as the target ED90 dose, it did not receive
the highest number of subjects since randomization of
ApoE4 carriers (approximately 70% of the subject population) to this dose was prohibited per implementation of
the Regulatory Authority request imposed between the
period of 300 and 350 randomized subjects. As a result,
the lecanemab 10 mg/kg biweekly group had fewer subjects compared to 10 mg/kg monthly with a lower percentage of ApoE4 carriers (30%) relative to all other
treatment groups (placebo 71%; 2.5 mg/kg biweekly 73%;
5 mg/kg monthly 77%; 5 mg/kg biweekly 91%; 10 mg/kg
monthly 89%). Demographic and baseline characteristics
were otherwise similar among treatment groups, with the
exception of more male subjects in the lecanemab group
relative to placebo (54% vs 42%; Table 1). Baseline characteristics for completers and discontinued subjects are
comparable across treatments for each group and can be
found in Tables S1-S2.
Discontinuations occurred in 23.7% for placebo- and
36.0% for lecanemab-treated subjects. Lecanemab

discontinuations were largely driven by ARIA-E events,
which resulted in discontinuation per protocol (N = 48,
46 lecanemab [1 for 2.5 mg/kg biweekly, 1 for 5 mg/kg
monthly, 3 for 5 mg/kg biweekly, 25 for 10 mg/kg
monthly, 16 for 10 mg/kg biweekly], 2 placebo) and by
implementation of the aforementioned Regulatory Authority request requiring discontinuation of subjects
who were ApoE4 carriers and who were on 10 mg/kg
lecanemab biweekly for less than 6 months (n = 25).
Discontinuations due to non-ARIA-E adverse events
were similar between placebo and lecanemab. Additional information can be found in the Supplementary Appendix (Figure S1).
Efficacy

The Bayesian model identified 10 mg/kg biweekly as the
effective dose 90% (ED90), defined as the simplest dose
that achieves ≥90% of the maximum treatment effect, at
the 12-month final Bayesian analysis (Table 2). The primary analysis conducted at month 12 of treatment for
all subjects indicated that the 10 mg/kg biweekly (ED90)
dose had a 64% probability of being better than placebo
with 25% less decline on ADCOMS at 12 months, missing the pre-specified 80% probability threshold for the
primary outcome (Table 2). As such, the primary endpoint was not met. Prespecified Bayesian analysis at 18

Table 1 Baseline characteristics. Baseline characteristics were reasonably well balanced across doses for each category, with the
exception of ApoE4 status. The imbalance in ApoE4 status on the 10 mg/kg monthly and 10 mg/kg biweekly doses is directly related
to the change in study design brought about by Health Authority interactions
Category

Lecanemab

Age, median (range), years

Placebo

2.5 mg/kg
biweekly

5 mg/kg
monthly

(N = 238)

(N = 52)

72 (50–89) 71 (50–86)

5 mg/kg
biweekly

10 mg/kg
Monthly

10 mg/kg
biweekly

Total
Lecanemab

(N = 48)

(N = 89)

(N = 246)

(N = 152)

(N = 587)

71 (55–84)

72 (52–87)

71 (53–90)

73 (51–88)

72 (50–90)

Female, n (%)

137 (58)

26 (50)

24 (50)

48 (54)

110 (45)

64 (42)

272 (46)

CDR Global = 0.5

200 (84)

44 (85)

40 (83)

77 (87)

210 (85)

133 (88)

504 (86)

Mild cognitive impairment

154 (65)

34 (65)

33 (69)

52 (58)

166 (68)

90 (59)

375 (64)

ApoE4 positive

169 (71)

38 (73)

37 (77)

81 (91)

218 (89)

46 (30)

420 (72)

Ongoing treatment with AChEIs and/
or memantine

128 (54)

28 (54)

25 (52)

56 (63)

131 (53)

79 (52)

319 (54)

ADCOMS, mean (SD)

0.37 (0.17) 0.39 (0.20)

0.40 (0.17)

0.39 (0.16)

0.37 (0.15)

0.37 (0.15)

0.38 (0.16)

ADAS-Cog14, mean (SD)

22.6 (7.7)

22.7 (8.1)

22.9 (7.7)

22.8 (6.7)

21.9 (7.3)

22.1 (7.7)

22.2 (7.4)

CDR-SB, mean (SD)

2.9 (1.5)

3.0 (1.6)

2.9 (1.4)

3.0 (1.3)

2.9 (1.3)

3.0 (1.4)

3.0 (1.4)

MMSE, mean (SD)

26.0 (2.3)

25.7 (2.5)

PET SUVr, mean (SD)†

1.40 (0.16) 1.41 (0.11)

*

25.3 (2.6)

25.6 (2.3)

25.7 (2.4)

25.6 (2.4)

25.6 (2.4)

1.42 (0.17)

1.40 (0.12)

1.42 (0.18)

1.37 (0.16)

1.41 (0.16)

CDR, Clinical Dementia Rating; ApoE4, apolipoprotein E4; AChEIs, acetylcholinesterase inhibitors; ADCOMS, the Alzheimer’s Disease Composite Score; ADAS-Cog14,
Alzheimer’s disease Assessment Scale-Cognitive Subscale; CDR-SB, Clinical Dementia Rating-Sum-of-Boxes; MMSE, Mini Mental State Examination; PET SUVr,
positron emission tomography standard uptake value ratio
*In the ADAS-Cog14 assessment, there were 237 subjects in the placebo group and 586 in the total lecanemab group (2.5 mg/kg biweekly = 52; 5 mg/kg
monthly = 47; 5 mg/kg biweekly = 89; 10 mg/kg monthly = 246; 10 mg/g biweekly = 152)
†
In the PET sub-study, there were 99 subjects in the placebo group and 216 in the total lecanemab group (2.5 mg/kg biweekly = 28; 5 mg/kg monthly = 28; 5 mg/
kg biweekly = 27; 10 mg/kg monthly = 89; 10 mg/g biweekly = 44)

Swanson et al. Alzheimer's Research & Therapy

(2021) 13:80

Page 7 of 14

Table 2 Bayesian Analysis of ADCOMS at 12 months—full analysis set
Treatment group

Total N

Change from baseline

Posterior quantities*

Mean

SD

Pr (Max)

Pr (ED90)

Pr Superiority

Pr (CSD)

ADCOMS—overall
Placebo control

229

0.113

0.012

–

–

–

–

2.5 mg/kg biweekly

51

0.134

0.024

0.009

0.009

0.216

0.028

5 mg/kg monthly

48

0.119

0.021

0.022

0.031

0.416

0.070

5 mg/kg biweekly

87

0.116

0.016

0.010

0.010

0.446

0.053

10 mg/kg monthly

242

0.084

0.011

0.318

0.386

0.961

0.479

10 mg/kg biweekly

143

0.077

0.014

0.642

0.563

0.976

0.638

Only subjects with non-missing data at both baseline and the relevant post-baseline visit are included in the change from baseline summary statistics
ADCOMS, Alzheimer’s Disease Composite Score; CSD, clinically significant difference; 25% better than placebo, ED90, dose regimen with at least 90% of the dmax
treatment effect; Max, maximum treatment effect; Pr, probability; Pr (Max), probability of being maximal effective dose; Pr (ED90), probability of being the ED90
dose; Pr (Superiority), probability to be superior to placebo by any magnitude; Pr (CSD), probability to be better than placebo by at least 25%
*Probabilities can be interpreted as a percentage (e.g., 0.10 is 10%)

months determined that the lecanemab 10 mg/kg biweekly dose had a 76% probability of being better than
placebo by 25% less decline on ADCOMS (Table S2).
Despite 10 mg/kg biweekly not having achieved the
threshold needed for superiority over placebo by at least
25%, additional prespecified Bayesian analyses indicated
a 97.6% and 97.7% probability of being superior to placebo by any magnitude at both 12 and 18 months,
respectively.
All reported p values are considered nominal because the primary endpoint was not met. Dosedependent reductions in amyloid PET SUVr values
were observed using florbetapir as the imaging agent

and whole cerebellum as reference region (Fig. 3a).
Binary (positive/negative) amyloid PET visual read
analyses indicated results consistent with SUVr data
(Fig. 3b). Least squares (LS) mean changes from baseline in amyloid PET SUVr normalized to whole cerebellum mask at 18 months were 0.004 for placebo,
and −0.094, −0.131, −0.197, −0.225, and −0.306 for
lecanemab 2.5 mg/kg biweekly, 5 mg/kg monthly, 5
mg/kg biweekly, 10 mg/kg monthly, and 10 mg/kg biweekly groups, respectively. The respective LS mean
differences from placebo for the individual lecanemab
treatment groups were −0.099, −0.136, −0.201, −0.229,
and −0.310 (P < 0.001 for all doses).

Fig. 3 Change from baseline in brain amyloid pathophysiology. Results as measured by amyloid PET SUVr are shown in a. Outcomes from the
qualitative (binary) visual read of the PET scans for conversion of brain amyloid pathology from positive to negative are depicted in b. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001 (all nominal). For PET analysis, N = 306 at 12 months and N = 288 at 18 months. The PET substudy was
optional, so only a portion of the total enrolled subject population opted to participate
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The results for the Bayesian analyses for reduction of
clinical decline at 18 months compared to placebo for
10 mg/kg biweekly on ADCOMS (27%; with 97.7% probability to be superior to placebo), CDR-SB (33%; with
96.4% probability to be superior to placebo), and ADASCog14 (56%, with 98.8% probability to be superior to
placebo) were similar to the results from the corresponding frequentist analyses for clinical measures when
comparing mean change from baseline and LS mean
data (additional data found in Tables S3, S4, S5, S6, S7,
S8, S9). Figure 4 shows the time course of effects according to frequentist analyses for ADCOMS, CDR-SB, and
ADAS-Cog14 at the two doses the Bayesian algorithm
determined to be the most meaningful (i.e., 10 mg/kg biweekly and monthly lecanemab doses were allocated the
majority of subjects; these two doses are shown for illustrative purposes and data for all dose groups are presented in Figures S2 and S3). In the conventional
analyses, lecanemab showed dose-dependent reduction in
change from baseline on ADCOMS over 18 months (Figure S2), with 30% (P =0.034) less clinical decline compared
to placebo at 10 mg/kg biweekly and 15% (P = 0.23) less
decline at the intermediate dose of 10 mg/kg monthly
(Fig. 4a). Results for the 3 lowest doses of lecanemab did
not differ from placebo (Figure S2). Lecanemab reduced
clinical decline on CDR-SB, with 26% less decline (P =
0.125) at 10 mg/kg biweekly and 17% (P =0.255) with 10
mg/kg monthly, compared to placebo, but these differences did not reach nominal significance (Fig. 4b). Lecanemab at 10 mg/kg biweekly reduced clinical decline on
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ADAS-Cog14 (Fig. 4c) over 18 months, with 47% (P =
0.017) less decline compared to placebo. The intermediate
dose of 10 mg/kg monthly decreased clinical decline by
6% (P = 0.74) on ADAS-Cog14 (Fig. 4a). Numerical differences from placebo were noted as early as 6 months and
were maintained over the 18 months of treatment. Lecanemab at 10 mg/kg monthly was an intermediate dose on
all clinical measures. Data between the mild AD dementia
and the MCI subgroups within the study population were
generally consistent but limited and difficult to interpret
due to small sample size (Tables S10, S11, S12).
Marginally greater total hippocampal volume reduction (7.56% increased volume decline) was observed at
10 mg/kg biweekly compared to placebo without nominal significance (Table S13; Figure S4A;). Whole brain
volume and ventricular volume results reflect increased
volume decline in the treatment groups compared to the
placebo group (Table S14-S15; Figure S4B-C).
As a post hoc sensitivity analysis to address the imbalance in ApoE4 carriers introduced by the change in allocation rules in response to regulatory input, we analyzed
the combined 10 mg/kg dose groups (biweekly and
monthly). The analysis for combining both of the 10 mg/
kg dose groups was pre-specified and resulted in an
ApoE4 carrier balance that approximated the ApoE4 balance of the placebo group and the overall population. Effect sizes were attenuated but favored lecanemab in the
combined scenario compared to 10 mg/kg biweekly
alone due to the addition of a large number of subjects
on a dose (10 mg/kg monthly) with sub-maximum effect

Fig. 4 Efficacy assessments. a Change from baseline for 10 mg/kg biweekly and monthly doses in the Alzheimer’s Disease Composite Score
(ADCOMS). The MMRM used treatment group, visit, clinical subgroup (MCI due to AD, Mild AD), the presence or absence of ongoing AD
treatment at baseline, ApoE4 status (positive, negative), region, treatment group-by-visit interaction as factors, and baseline value as covariate.
*P < 0.05 (nominal). The primary analysis conducted at month 12 of treatment for all subjects indicated that the 10 mg/kg biweekly dose had a
64% probability to be better than placebo by 25% on ADCOMS at 12 months, missing the pre-specified 80% probability threshold for success.
Bayesian analysis at 18 months determined that the lecanemab 10 mg/kg biweekly dose had a 76% probability of being better than placebo by
25% on ADCOMS. In addition, Bayesian analyses indicated a 98% probability of being superior to placebo by any magnitude at both 12 and 18
months, respectively, which is consistent with subsequent conventional analysis results. b Results for 10 mg/kg biweekly and monthly doses on
CDR-SB. The number of subjects that were assessed at each time point are indicated in the table. The MMRM used treatment group, visit, clinical
subgroup (MCI due to AD, Mild AD), the presence or absence of ongoing AD treatment at baseline, ApoE4 status (positive, negative), region,
treatment group-by-visit interaction as factors, and baseline value as covariate. *P < 0.05 (nominal). c Results for 10 mg/kg biweekly and monthly
doses on ADAS-Cog14. The number of subjects that were assessed at each time point are indicated in the table. The MMRM used treatment
group, visit, clinical subgroup (MCI due to AD, Mild AD), the presence or absence of ongoing AD treatment at baseline, ApoE4 status (positive,
negative), region, treatment group-by-visit interaction as factors, and baseline value as covariate. *P < 0.05 (nominal)
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(Tables S4-S5, S7, S9, and S13). In frequentist analysis,
at 18 months, lecanemab in the combined 10 mg/kg dose
groups decreased clinical decline by 20% on ADCOMS
(P =0.053; Table S9), 22% on ADAS-Cog14 (P =0.154;
Table S12), and 20% on CDR-SB (P =0.119; Table S10)
versus placebo. The LS mean difference in amyloid PET
SUVr at 18 months of the combined lecanemab 10 mg/
kg groups from placebo was −0.253 (P < 0.001). Recognizing that the study design was changed early in the
study, the impact of the ApoE4 carrier imbalance for the
most effective 10 mg/kg biweekly (ED90) dose was explored in Bayesian sensitivity analyses comparing effects
of lecanemab in ApoE4 carriers versus non-carriers.
Lecanemab at 10 mg/kg biweekly showed greater reductions of cognitive decline in ApoE4 positive subjects versus ApoE4-negative subjects compared to placebo
(Table S16). Sensitivity analyses were consistent with results from key secondary MMRM analyses (Table S17).
CSF biomarker analyses in the pooled 10 mg/kg dose
arms showed an increase in CSF Aβ42 and decrease in
p-tau relative to placebo, whereas inconsistent results
were noted at 12 months and 18 months for total tau
(Fig. 5a–c). The LS mean difference at 18 months of the
combined lecanemab 10 mg/kg treatment groups from
placebo was 205.6 (P < 0.001), 18.8 (P = 0.670), and − 12.3
(P = 0.013) for Aβ (1–42), t-tau, and p-tau, respectively.
These findings were supported by post-hoc analysis of
CSF neurogranin and NfL, which were conducted to further evaluate the impact of lecanemab on downstream
pathophysiology of AD (Figure S5A-B).
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Safety

Lecanemab was generally well-tolerated with ARIA-E incidence <10% at the highest doses for the overall population and 14.3% for ApoE4-positive subjects (Table 3).
Apart from ARIA-E and infusion reactions, the incidence rates of adverse events, serious adverse events,
and treatment-emergent adverse events were consistent
with those expected for this population and similar
across placebo and lecanemab treatment groups. The
most common treatment-emergent adverse events were
infusion reaction (3.3% for placebo, 5.8% for 2.5 mg/kg
biweekly, 7.8% for 5 mg/kg monthly, 12.0% for 5 mg/kg
biweekly, 22.9% for 10 mg/kg monthly, and 19.9% for 10
mg/kg biweekly) and ARIA-E (0.8% for placebo, 1.9% for
2.5 mg/kg biweekly, 2.0% for 5 mg/kg monthly, 3.3% for
5 mg/kg biweekly, 9.9% for 10 mg/kg monthly, and 9.9%
for 10 mg/kg biweekly). Infusion reactions were mostly
mild to moderate (Grade 1–2) and typically responded
to prophylactic treatment. There were no relevant treatment differences between lecanemab and placebo in
labs, electrocardiograms, or vital signs. Thirty-seven of
the total 48 ARIA-E cases (2 for placebo; 46 for lecanemab) were in ApoE4+ subjects. There were 5 cases of
symptomatic ARIA-E (lecanemab: 5/46 [11%]), which
generally consisted of headache, visual disturbances, or
confusion. Radiologic severity for symptomatic cases
were one severe at 2.5 mg/kg biweekly; one mild at 10
mg/kg monthly; one moderate at 10 mg/kg biweekly;
and two severe at 10 mg/kg biweekly. The 2.5 mg/kg biweekly case was considered a non-serious adverse event;

Fig. 5 Change from baseline in CSF biomarker measures. a Change from baseline in CSF Aβ1–42 measures. The combined 10 mg/kg monthly and
10 mg/kg biweekly group is compared versus placebo. The number of subjects that were assessed at each time point are indicated in the table.
The MMRM used treatment group, visit, clinical subgroup (MCI due to AD, Mild AD), the presence or absence of ongoing AD treatment at
baseline, ApoE4 status (positive, negative), region, treatment group-by-visit interaction as factors, and baseline value as covariate. *P < 0.001. b
Change from baseline in p-tau measures. The combined 10 mg/kg monthly and 10 mg/kg biweekly group is compared versus placebo. The
number of subjects that were assessed at each time point are indicated in the table. The MMRM used treatment group, visit, clinical subgroup
(MCI due to AD, Mild AD), the presence or absence of ongoing AD treatment at baseline, ApoE4 status (positive, negative), region, treatment
group-by-visit interaction as factors, and baseline value as covariate. *P < 0.001, **P = 0.005. c Change from baseline in t-tau measures. The
combined 10 mg/kg monthly and 10 mg/kg biweekly group is compared versus placebo. The number of subjects that were assessed at each
time point are indicated in the table. The MMRM used treatment group, visit, clinical subgroup (MCI due to AD, Mild AD), the presence or
absence of ongoing AD treatment at baseline, ApoE4 status (positive, negative), region, treatment group-by-visit interaction as factors, and
baseline value as covariate. *P = 0.029
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Table 3 The summary of treatment emergent adverse events and amyloid-related imaging abnormalities-edema (ARIA-E).
Lecanemab was generally well-tolerated with similar incidence rates of AEs and SAEs between placebo and lecanemab, and these
events were consistent with the subject population. The most common TEAEs were infusion-related reaction (most were mild to
moderate in severity, most responded to prophylactic treatment, and few led to discontinuation) and ARIA-E (most were mild to
moderate in severity, and were required to discontinue treatment, but encouraged to continue efficacy assessments). Incidence of
treatment-related TEAE were similar for placebo and lecanemab for non-ARIA-E-related events
Lecanemab
Category

Placebo
(n = 245)
n (%)

2.5 mg/kg
Biweekly
(n = 52)
n (%)

5 mg/kg
Monthly
(n = 51)
n (%)

5 mg/kg
Biweekly
(n = 92)
n (%)

10 mg/kg
Monthly
(n = 253)
n (%)

10 mg/kg
Biweekly
(n = 161)
n (%)

Any TEAE

216 (88.2)

46 (88.5)

48 (94.1)

81 (88.0)

238 (94.1)

39 (86.3)

Treatment-related TEAE

65 (26.5)

23 (44.2)

25 (49.0)

31 (33.7)

135 (53.4)

76 (47.2)

Serious adverse event

43 (17.6)

10 (19.2)

4 (7.8)

16 (17.4)

31 (12.3)

25 (15.5)

Deaths

2 (0.8)

2 (3.8)

0

1 (1.1)

2 (0.8)

0

AE leading to discontinuation

15 (6.1)

7 (13.5)

4 (7.8)

10 (10.9)

47 (18.6)

24 (14.9)

ARIA-E

2 (0.8)

1 (1.9)

1 (2.0)

3 (3.3)

25 (9.9)

16 (9.9)

ApoE4-positive (n = 436)

2 (1.1)

1 (2.6)

1 (2.5)

3 (3.6)

23 (10.2)

7 (14.3)

ApoE4-negative(n = 112)

0

0

0

0

2 (7.1)

9 (8.0)

TEAE, treatment emergent adverse event; ARIA-E, amyloid-related imaging abnormalities-edema; ApoE4, apolipoprotein E4

all other symptomatic cases were considered serious adverse events. Most ARIA-E (60%) occurred within the
first 3 months of treatment and were mostly mild-tomoderate (89%) in radiologic severity. All ARIA-E cases
resolved, with a typical time course of 4–12 weeks.
In this study, ARIA-H (new cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis) regardless of the presence of ARIA-E were
observed in 13 (5.3%) subjects in the placebo group
(N = 245) compared to 65 (10.7%) subjects in the lecanemab groups (N = 609). Although there was a higher incidence of ARIA-H on lecanemab than placebo, there
were no dose-related trends in the incidence of ARIA-H
on lecanemab (2 [3.8%], 7 [13.7%], 17 [18.5%], 28
[11.1%], and 11 [6.8%] subjects in the 2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg
monthly, and 10 mg/kg biweekly groups, respectively).
As seen for the incidence of ARIA-E, the incidence of
ARIA-H on lecanemab was higher in ApoE4 carriers
(N = 436) (57 [13.1%] subjects) than in ApoE4 noncarriers (N = 173) (8 [4.6%] subjects). ARIA-H occurred
concurrently with ARIA-E, or after the onset of ARIA–E
in 1 (0.4%) subject in the placebo group; 1 (2.0%), 1
(1.1%), 13 (5.1%), and 7 (4.3%) subjects in the 5 mg/kg
monthly subjects, 5 mg/kg biweekly, 10 mg/kg monthly,
and 10 mg/kg biweekly groups, respectively; and in 22
(3.6%) subjects in the lecanemab treatment groups overall. There were no symptomatic cases of ARIA-H in
Study 201.

Discussion
This was the first randomized phase 2 clinical trial
evaluating subjects with early Alzheimer’s disease

receiving treatment with lecanemab, an anti-protofibril
antibody that targets soluble aggregated forms of amyloid beta (Aβ), including oligomers and protofibrils.
Bayesian response adaptive randomization was employed
for efficient subject allocation to the most effective
dose(s) in the trial. The 10 mg/kg biweekly and monthly
doses were identified as potential effective dose 90%
(ED90) doses early in the study, with 10 mg/kg biweekly
dose determined to be the final ED90 dose (defined as
the simplest treatment group that achieves at least 90%
of the modeled maximum treatment effect). The primary
endpoint, requiring an 80% probability of ≥25% reduction in clinical decline compared to placebo in a Bayesian analysis of ADCOMS at 12 months, was not met.
Results from prespecified key secondary endpoint analyses demonstrated that lecanemab reduced brain amyloid and showed early and sustained activity for 10 mg/kg
biweekly lecanemab across the 18-month treatment
period for several clinical measures of AD. Importantly,
Bayesian and conventional statistical approaches yielded
consistent results for lecanemab on clinical decline.
Lecanemab was generally well-tolerated, with the key adverse event being ARIA-E with an incidence rate of less
than 10% at the two highest doses for the overall
population.
Dose-dependent and robust reductions in amyloid
PET SUVr values were observed using florbetapir as the
imaging agent across all doses (nominal P < 0.0001 at 18
months of treatment for all doses). The baseline PET
SUVr for the 10 mg/kg biweekly group was 1.37, with a
mean change of −0.31 at 18 months, suggesting on average, that subjects treated with this dose fall below the
SUVr threshold for amyloid-PET positivity for
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florbetapir. Consistent with PET SUVr results, a substantially larger proportion of subjects on lecanemab 10
mg/kg biweekly converted (by visual read) to amyloid
negative (81%) compared to placebo (22%; placebo variability is generally attributed to variability associated
with borderline amyloid PET positive cases).
Volumetric MRI results indicated that lecanemab
treatment at 10 mg/kg biweekly marginally increased
hippocampal volume loss; effects on increased whole
brain volume loss and total ventricular volume increase
were more pronounced. While these effects are generally
consistent with literature reports for other amyloidtargeting agents [22–24], the reasons for these observations are unclear, but may be related to antibody profile
and Aβ clearance, as has been suggested previously [25].
The long-term implications of these findings are unknown and may be assessed in longer term follow-up
and in the phase 3 study BAN2401-G000-301 (Clarity
AD).
In a CSF substudy, AD-related changes in Aβ1–42 and
p-tau levels were nominally increased and decreased respectively (both moving to become more normal) in the
combined 10 mg/kg lecanemab dose groups relative to
placebo at 18 months, whereas results for t-tau did not
differ. AD diagnosis is associated with increased plaque
burden in the brain and a decrease in Aβ1–42 monomers in CSF due to sequestration of monomeric Aβ1–42
into amyloid plaques [26]. The increase in CSF Aβ1–42
observed in Study 201 may reflect changes in the dynamics of amyloid aggregation or normalization of
monomeric amyloid levels related to amyloid plaque
clearance. Mechanistic studies are needed to better
understand the meaning of the increase in CSF Aβ1–42
and how it relates to the treatment effect. Lecanemabmediated effects on p-tau are consistent with previous
reports involving amyloid therapies [27–29] and suggest
that targeting amyloid may influence the downstream
neurodegenerative processes associated with AD. We included the post hoc analysis of CSF neurogranin and
NfL that were not prospectively defined as secondary
endpoints in this study. Both these measures showed
changes consistent with a treatment effect. While these
biomarkers were not established at the time the study
was initiated, we consider it important to include the full
complement of biomarker results here, as neurogranin
and NfL are rapidly gaining acceptance as markers of
neurodegeneration [30], and they may help provide context to the overall results in Study 201.
Most previously published studies using other putative
disease-modifying agents for AD did not show appreciable clinical efficacy in phase 3 [19, 31]. In this study,
it is considered that several features helped to optimize
the detection of clinical differences in a relatively slowly
progressing early Alzheimer’s disease population.
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Importantly, eligibility requirements dictated that all
subjects have confirmed amyloid pathology, a feature
lacking in some phase 3 studies. Moreover, the lecanemab mechanism of action is distinct among other antiamyloid agents in that it has high selectivity for soluble
aggregate species of Aβ compared to monomeric amyloid, with moderate selectivity over fibrillar amyloid; a
profile thought to convey an advantage in selectively targeting the most toxic pathologic amyloid species. Finally,
the Bayesian design ensured that more subjects be allocated to the most effective dose or doses (i.e., potential
ED90 dose(s)), while ADCOMS was used as a sensitive
tool to help inform frequent response adaptive allocations through early detection of clinical potential [21].
The 10 mg/kg biweekly group, despite being limited in
size and ApoE4+ balance, showed nominally significant
differences versus placebo on ADCOMS and ADASCog14 at 18 months of treatment. The 10 mg/kg
monthly group demonstrated intermediate effects relative to placebo across assessments, but these differences
were not nominally significant. None of the other dose
groups differed from placebo most likely due to the relatively small sample size allocated to these sub-optimal
doses by the Bayesian adaptive randomization algorithm.
Limitations

There are some important limitations for this study.
Most notably, a small number of symptomatic ARIA-E
cases at 10 mg/kg biweekly prompted one Regulatory
Authority to request that subsequent ApoE4+ subjects
(approximately 70% of the overall study population) not
be randomized to the 10 mg/kg biweekly dose. An additional component to the request required that all
ApoE4+ subjects on 10 mg/kg biweekly who were on
study but who had not yet reached 6 months of treatment be immediately discontinued (N = 25 subjects). Implementation of these actions led to early (initiated
between 300 and 350 randomized participants) and significant changes to the study design that resulted in a
marked imbalance in the number of ApoE4+ subjects on
10 mg/kg biweekly (30% ApoE4+ subjects). The Bayesian
algorithm identified 10 mg/kg biweekly as the ED90 dose
despite this imposed design limitation. The constraints in
this analysis were specifically associated with the ED90
dose and therefore could have had an impact on the ability
to interpret the results. The safety and efficacy of 10 mg/
kg biweekly lecanemab is currently being evaluated in an
open label extension to this study, and in the phase 3 lecanemab Clarity AD study, where there are no dosing restrictions based on ApoE status in either study.
ARIA-E rates were ~ 10% for both the 10 mg/kg
monthly and 10 mg/kg biweekly doses and < 15% for
ApoE4-positive subjects. The assessment of early ARIAE cases that led to Study 201 design changes were
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determined based on limited experience and understanding of lecanemab at the time of trial initiation.
Additional experience since that time, both with lecanemab and other anti-amyloid monoclonal antibodies, has
reframed the understanding and management of ARIAE. In general, ARIA-E is dose- and ApoE4-status
(ApoE4+ > ApoE4-) dependent, is observed early in
treatment, is predominantly asymptomatic, can be effectively monitored, and is radiologically reversible on MRI.
Symptomatic cases generally involve mild and transient
symptoms that resolve without sequelae; vigilance is
continuing to improve understanding of the risks and
management of this effect. Based on the emerging clinical understanding of ARIA-E and its management, the
full 10 mg/kg biweekly dose is implemented in ApoE4
carriers in the open label extension to this study, and in
the phase 3 lecanemab Clarity AD study, with appropriate monitoring and management criteria.

Conclusions
This study was designed as an 18-month, proof-ofconcept study. The study explored the dose response of
lecanemab over three dose levels and two dosing regimens
with the objective to establish the most effective (ED90)
dose of lecanemab based on ADCOMS. A 12-month primary endpoint was utilized to allow for the opportunity to
accelerate the development program, if possible, through
the use of a Bayesian adaptive design; however, the study
was to complete the blinded 18-month treatment period
regardless of the 12-month outcome. The Bayesian design
identified 10 mg/kg biweekly as the ED90 dose. Proof of
concept was supported through prespecified key secondary endpoint analyses, where lecanemab treatment resulted in a dose dependent and consistent reduction in
clinical decline relative to placebo across a number of clinical endpoints according to Bayesian and frequentist approaches. These effects were accompanied by a dosedependent reduction in brain amyloid PET over 18 months
of treatment and were reinforced by additional CSF biomarker results. Taken together, the findings in this
double-blind trial on multiple cognitive endpoints and
biomarkers are supportive of the therapeutic concept for
the targeting specific oligomeric species (protofibrils) in
the process of pathophysiological amyloid generation in
AD. The confirmation of the effects of lecanemab are being evaluated in the Phase 3 Clarity AD study in early Alzheimer’s disease.
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